Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 2, 2013, Pages 124-133

  Vera Llonch, M ^a   Martin, M ^a   Aggarwal, J ^b   Donepudi, M ^a   Bayliss, M ^c   Goss, T ^b   Younossi, Z ^d  

^a VERTEX PHARMACEUTICALS   (United States)

^b Boston Healthcare Associates Inc   (United States)

^c QualityMetric Incorporated   (United States)

^d BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ASSESSMENT TOOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; EQ 5D 3L QUESTIONNAIRE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PAIN; PHYSICAL ACTIVITY; POST HOC ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF CARE; TREATMENT DURATION; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; HEALTH STATUS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; TIME; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEALTH STATUS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RECOMBINANT PROTEINS; RIBAVIRIN; TIME FACTORS; VIRAL LOAD;

EID: 84879237873     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12354     Document Type: Article

References (47)

1. Chack E, Talal AH, Sherman KE, et al,. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090-101.
2. Armstrong GL, Wasley A, Simard EP, et al,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
3. Davis GL, Alter MJ, El-Serag H, et al,. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21.
4. Ghany MG, Strader DB, Thomas DL, et al,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
5. Sangiovanni A, Prati GM, Fasani P, et al,. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-10.
6. Di Bisceglie AM, Lyra AC, Schwartz M, et al,. Liver Cancer Network. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003; 98: 2060-3.
7. Shiffman ML, Saab S, Feng S, et al,. Liver and intestine transplantation in the United States, 1995-2004. Am J Transplant 2006; 6: 1170-87.
8. McHutchison JG, Ware JE, Bayliss MS, et al,. The effects of interferon alpha 2-b in combination with ribavirin and health related quality of life and productivity. J Hepatol 2001; 34: 140-7.
9. Bonkovsky HL, Woolley JM, and the Consensus Interferon Study Group. Reduction in health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 264-70.
10. Svirlith N, Pavic S, Terzic D, et al,. Reduced quality of life in patients with chronic viral liver disease as assessed by the SF-12 questionnaire. J Gastrointest Liver Dis 2008; 17: 405-9.
11. DiBonaventura MD, Wagner JS, Yuan Y, et al,. Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ 2010; 13: 709-18.
12. Hsu PC, Federico CA, Krajden M, et al,. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol 2012; 27: 149-57.
13. Chong CA, Gulamhussein A, Heathcote EJ, et al,. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 630-8.
14. Bezemer G, van Gool AR, Verjeij-Hart E, et al,. Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life: an international, multicenter, randomized, controlled study. BMC Gastroenterol 2012; 12: 11.
15. Chong CA, Gulamhussein A, Heathcote EJ, et al,. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 630-8.
16. Foster GR, Goldin RD, Thomas HC,. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-12.
17. Miller ER, Hiller JE, Shaw DR,. Quality of life in HCV-infection: lack of association with ALT levels. Aust N Z J Public Health 2001; 25: 355-61.
18. Ware JE Jr, Bayliss MS, Mannocchia M, et al,. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30: 550-5.
19. Carithers RL, Sugano D, Bayliss M,. Health assessment for chronic HCV: results of HQL. Dig Dis Sci 1996; 41 (Suppl. 12): 75S-80S.
20. Davis GL, Balert LA, Schiff ER, et al,. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 1994; 16: 334-43.
21. Bayliss MS, Gandek B, Bungay KM, et al,. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998; 7: 39-55.
22. Wachtel T, Piette J, Mor V, et al,. Quality of life in persons with human immunodeficiency virus infection: measurement by the Medical Outcomes Study instrument. Ann Intern Med 1992; 116: 129-37.
23. Forton DM,. Hepatitis C treatment-clearing the mind. J Hepatol 2011; 56: 513-4.
24. Senzolo M, Schiff S, D'Aloiso CM, et al,. Neuropsychological alterations in hepatitis C infection: the role of inflammation. World J Gastroenterol 2011; 17: 3369-74.
25. Bouffard P, Hayashi P, Acevedo R, et al,. Hepatitis C virus is detected in monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients. J Infect Dis 1992; 166: 1276-82.
26. Younossi Z, Kallman J, Kincaid J,. The effects of HCV infection and management on health-related quality of life. Hepatology 2007; 45: 806-16.
27. Rodger AJ, Jolley D, Thompson SC, et al,. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30: 1299-301.
28. Rasenack J, Zeuzem S, Feinman SV, et al,. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21: 341-9.
29. Hassanein T, Cooksley G, Sulkowski M, et al,. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-81.
30. Bernstein D, Kleinman L, Barker CM, et al,. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-8.
31. Dusheiko B,. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26 (Suppl. 1): 112S-21S.
32. Zeuzem S, Feinman VS, Rasenack J, et al,.; for the Pegasys International Study Group. Peginterferon alpha-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
33. Spiegel BM, Younossi ZM, Hays RD, et al,. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790-800.
34. John-Baptiste AA, Tomlinson G, Hsu PC, et al,. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009; 104: 2439-48.
35. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
36. INCIVEK™ [US prescribing information]. Cambridge, MA: Vertex Pharmaceuticals Incorporated; June 2012.
37. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
38. ™ Index Score. August 2005. Available at: http://www.ahrq.gov/rice/EQ5Dscore.htm. Accessed August 28, 2012.
39. Fryback DG, Dunham NC, Palta M, et al,. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care 2007; 45: 1162-70.
40. Luo N, Johnson JA, Coons SJ,. Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med Care 2010; 48: 365-71.
41. Sulkowski MS, Roberts S, Afdhal N, et al,. Ribavirin dose modification in treatment-naïve and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies. J Hepatol 2012; 56 (Suppl. 2): S459-60.
42. Córdoba J, Flavià M, Jacas C, et al,. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003; 39: 213-38.
43. Neary MP, Cort S, Bayliss S, et al,. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999; 19 (Suppl. 1): 77-85.
44. Fontana RJ, Moyer CA, Sonnad S, et al,. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol 2001; 96: 170-8.
45. Hunt CM, Dominitz JA, Bute BP, et al,. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42: 2482-6.
46. Arora S, O'Brien C, Zeuzem S, et al,. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol 2006; 21: 406-12.
47. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24. [Erratum: N Engl J Med. 2011;365:1551].